Gemfibrozil
規格
25812-30-0CAS番号
247-280-2EC番号
5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acidIUPAC名
C15H22O3化学式
250.33 g/mol分子量
gemfibrozil; 25812-30-0; 5-(2,5-Dimethylphenoxy)-2,2-dimethylpentanoic acid; Lopid; Lipur; Jezil; CI-719; Gemfibrozilo; Gemlipid; Gemfibrozilum; Pentanoic acid, 5-(2,5-dimethylphenoxy)-2,2-dimethyl-; 2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid; Gen-Fibro; DTXSID0020652; 2,2-Dimethyl-5-(2,5-xylyloxy)valeriansaeure; CI 719; 2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansaeure; NSC-757024; Valeric acid, 2,2-dimethyl-5-(2,5-xylyloxy)-; Gemfibrosil; Q8X02027X3; DTXCID20652; CHEBI:5296; Lopid R; ApoGemfibrozil; GenGemfibrozil; Genlip; NuGemfibrozil; Apo Gemfibrozil; Gen Gemfibrozil; Nu Gemfibrozil; Novo Gemfibrozil; PMS Gemfibrozil; Gemfibrozil, SBPA; Gemfibrozil, GenRX; Bayvit, Gemfibrozilo; Gemfibrozil, Healthsense; CI719; Emfib; RefChem:57800; C10AB04; 247-280-2; 657-339-8; Decrelip; MFCD00079335; Bolutol; Apo-Gemfibrozil; Gemfibrozil (Standard); Cholespid; Gemfibril; Gemfibromax; Fibratol; Fibrocit; Lipazil; Litarek; Trialmin; Ausgem; Pilder; CHEMBL457; 2,2-Dimethyl-5-(2,5-dimethylphenoxy)pentanoic acid; MLS000028421; Renabrazin; Clearol; Elmogan; Fetinor; Gemnpid; Innogen; Ipolipid; Lanaterom; Lifibron; Lipigem; Lipizyl; Lipozid; Micolip; Normolip; Progemzal; Reducel; Regulip; Sinelip; Synbrozil; Taborcil; Tentroc; Brozil; Lipira; Gozid; Hidil; Gemd; WL-Gemfibrozil; Gevilon Uno; Low-Lip; 5-(2,5-dimethylphenoxy)-2,2-dimethyl-pentanoic acid; 5-[(2,5-dimethylphenyl)oxy]-2,2-dimethylpentanoic acid; Gem-S; NCGC00016794-09; SMR000058393; CAS-25812-30-0; Gemfibrozilum [INN-Latin]; Gemfibrozilo [INN-Spanish]; Organolipid; Innogem; CCRIS 318; Lopid (TN); TEVA-A; SR-01000000056; EINECS 247-280-2; BRN 1881200; Gemcor; Gemfibrozil (JAN/USP/INN); Hipolixan;; Gemfibrozil CRS; Lipozid;; Gemcor;; UNII-Q8X02027X3; HSDB 7735; Emfib;; Lipur;; Lopid;; 4TX; Gemfibrozil [USAN:USP:INN:BAN]; Prestwick_637; Gemfibrozil (Lopid); Spectrum_000825; CPD000058393; GEMFIBROZIL [MI]; 114413-98-8; Opera_ID_1658; Prestwick0_000214; Prestwick1_000214; Prestwick2_000214; Prestwick3_000214; Spectrum2_001097; Spectrum3_000440; Spectrum4_000562; Spectrum5_000750; Spectrum5_001991; GEMFIBROZIL [INN]; GEMFIBROZIL [JAN]; GEMFIBROZIL [HSDB]; GEMFIBROZIL [IARC]; GEMFIBROZIL [USAN]; GEMFIBROZIL [VANDF]; SCHEMBL4813; GEMFIBROZIL [MART.]; BSPBio_000227; BSPBio_002060; GEMFIBROZIL [USP-RS]; GEMFIBROZIL [WHO-DD]; KBioGR_000964; KBioSS_001305; 2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeric Acid; MLS001055364; MLS006011850; DivK1c_000138; SPECTRUM1500313; SPBio_001174; SPBio_002148; BPBio1_000251; CI-7; GTPL3439; orb1225491; orb1308681; orb3025505; SCHEMBL9481043; Gemfibrozil, analytical standard; SCHEMBL29398115; HMS500G20; HY-B0258R; KBio1_000138; KBio2_001305; KBio2_003873; KBio2_006441; KBio3_001280; GEMFIBROZIL [ORANGE BOOK]; NINDS_000138; GEMFIBROZIL [EP MONOGRAPH]; GLXC-07494; HMS1568L09; HMS1920B07; HMS2090K14; HMS2091H11; HMS2095L09; HMS2230H24; HMS3259M12; HMS3655C06; HMS3712L09; HMS5079L18; Pharmakon1600-10500313; GEMFIBROZIL [USP MONOGRAPH]; HY-B0258; MSK10081; Tox21_110613; Tox21_201997; Tox21_302784; BBL010807; BDBM50110590; CCG-40111; DL-414; EBC-06088; NSC757024; s1729; SBB012457; STK618740; AKOS001606691; Gemfibrozil for system suitability CRS; Tox21_110613_1; AB03034; AC-4225; DB01241; FD23652; KS-5192; NC00565; NSC 757024; IDI1_000138; NCGC00016794-01; NCGC00016794-02; NCGC00016794-03; NCGC00016794-04; NCGC00016794-05; NCGC00016794-06; NCGC00016794-07; NCGC00016794-08; NCGC00016794-10; NCGC00016794-11; NCGC00016794-13; NCGC00016794-14; NCGC00016794-20; NCGC00022722-03; NCGC00022722-04; NCGC00022722-05; NCGC00022722-06; NCGC00022722-07; NCGC00256601-01; NCGC00259546-01; ST072198; SY052512; Gemfibrozil 100 microg/mL in Acetonitrile; SBI-0051391.P003; AB00052003; CS-0694895; G0368; G1749; NS00010281; SW196802-3; EN300-97098; C07020; D00334; D83091; AB00052003-15; AB00052003-16; AB00052003_17; AB00052003_18; F054267; Q384295; SR-01000000056-3; SR-01000000056-4; SR-01000000056-6; SR-01000000056-7; 2,2-Dimethyl-5-(2,5-dimethylphenoxy)-pentanoic acid; 2,2-DIMETHYL-5-(2,5-XYLYLOXY) VALERIC ACID; BRD-K11129031-001-05-1; BRD-K11129031-001-26-7; BRD-K11129031-001-27-5; Z1259021151; Gemfibrozil, British Pharmacopoeia (BP) Reference Standard; Gemfibrozil, European Pharmacopoeia (EP) Reference Standard; Gemfibrozil, United States Pharmacopeia (USP) Reference Standard; Gemfibrozil, Pharmaceutical Secondary Standard; Certified Reference Material; Gemfibrozil for system suitability, European Pharmacopoeia (EP) Reference Standard別名
Gemfibrozilを含む製品
겜피질캅셀(겜피브로질)[수출명:Lipiden Cap.](수출용)GEMFIBROZILO TARBIS 900 mg COMPRIMIDOS RECUBIERTOS CON PELICULA EFGGEMFIBROZILO TARBIS 600 mg COMPRIMIDOS RECUBIERTOS CON PELICULA EFGTRIALMIN 900 mg COMPRIMIDOS RECUBIERTOS CON PELICULATRIALMIN 600 mg COMPRIMIDOS RECUBIERTOS CON PELICULALOPID 900 mg COMPRIMIDOS RECUBIERTOS CON PELICULALOPID 600 mg COMPRIMIDOS RECUBIERTOS CON PELICULAGEMFIBROZILO STADA 900 mg COMPRIMIDOS EFGGEMFIBROZILO STADA 600 mg COMPRIMIDOS EFGLIPUR 450 mg, comprimé pelliculéBrezimedGemfibstad 300
1/5ページ
Gemfibrozilに関連するサービス
Gemfibrozilを販売する企業
CT
Công ty cổ phần dược phẩm WealpharViet NamCT
Công ty TNHH Abbott Healthcare Việt NamViet Nam1/4ページ